Drug Trial Radar · NCT05271409
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
139
Actual
Start
Aug 30, 2022
Primary completion
Nov 20, 2025
Study completion May 20, 2028
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Chugai Pharmaceutical
- First posted
- Mar 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period. Participants who experience an adjudicated relapse or complete the DB period can enter open-label extension (OLE) period. After the primary clinical cutoff date (CCOD), additional adolescent participants may be enrolled directly into the OLE period.
Conditions
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Interventions
SatralizumabDrug
Study drug will be administered by subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
PlaceboOther
Placebo will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time From Randomization to the First Occurrence of a MOGAD Relapse in the DB Treatment Period, as Determined by an Adjudication Committee (CEC)Time frame: Up to approximately 44 months
Locations
53 sites in 11 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California Irvine - Manchester Pavilion
Irvine, California
University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center)
Aurora, Colorado
Medstar Georgetown University Hospital
Washington D.C., District of Columbia
University of Florida College of Medicine Gainesville
Gainesville, Florida
Johns Hopkins
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis
Owosso, Michigan
Mayo Clinic - Rochester
Rochester, Minnesota
Washington University School of Medicine in St. Louis
St Louis, Missouri
NYU Langone
New York, New York
University of Cincinnati
Cincinnati, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio
Premier Neurology
Greenville, South Carolina
Medical College of Wisconsin
Milwaukee, Wisconsin
Brain and Mind Research Institute
Camperdown, New South Wales, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Perron Institute for Neurological and Translational Science
Nedlands, Western Australia, Australia
Hospital Universitario Gaffree e Guinle
Rio de Janeiro, Brazil
Instituto de Neurologia de Curitiba
Curitiba, Paraná, Brazil
Instituto do Cerebro do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Pesquisas Clinicas
São Paulo, São Paulo, Brazil
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
MUCH - Montreal Neurological Institute & Hospital
Montreal, Quebec, Canada
Hopital Pierre Wertheimer
Bron, France
CH de Bicêtre
Le Kremlin-Bicêtre, France
ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic
Berlin, Germany
St. Josef-Hospital, Klinik für Neurologie
Bochum, Germany
Vestische Kinder- und Jugendklinik Datteln
Datteln, Germany
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
Universitätsklinikum Mannheim
Mannheim, Germany
Klinikum Großhadern, LMU
Munich, Germany
Hadassah University Hospital Ein Kerem
Jerusalem, Israel
Fondazione Istituto Neurologico Mondino IRCCS
Pavia, Lombardy, Italy
Azienda Sanitaria Ospedaliera S. Luigi Gonzaga
Orbassano, Piedmont, Italy
Azienda Ospedaliera Universitaria Integrata Verona
Verona, Veneto, Italy
Chiba University Hospital
Chiba, Japan
Kyushu University Hospital
Fukuoka, Japan
Southern Tohoku Medical Clinic
Fukushima, Japan
Kobe University Hospital
Hyōgo, Japan
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.